Chemomab Therapeutics Ltd., an Israeli clinical-stage biopharma company, reports sustained operating losses amid ongoing R&D investment, with net losses narrowing in the most recent fiscal year. The absence of revenues reflects the company’s developmental status and limited public disclosure on its pipeline. Solid cash and current asset balances relative to liabilities underpin a strong liquidity position, supported by a reverse ADS ratio adjustment executed in 2025. Capital allocation focuses on research funding without dividends or share repurchases. Cybersecurity governance is robust, reflecting the sensitivity of proprietary data. With no explicit forward guidance, investors should monitor clinical milestones to gauge progress toward commercialization.